Jubilant Pharmova Limited — Updates, 25-10-2024: Press Release

Jubilant Pharmova Limited reported a 5% YoY increase in total income for Q2’FY25, reaching ₹1,774 Cr, driven by growth in Radiopharma and drug discovery. EBITDA surged 19% YoY to ₹311 Cr, with margins improving to 17.5%. Normalized PAT showed a significant rise of 65% YoY to ₹103 Cr. The company announced a strategic partnership with Pierre Fabre to enhance its European presence and continues to focus on expanding its operational capacities across various segments.